12/2016 - Transfer
of project business to YUMAB
We thank all our customers for your trust in mAb-factory technologies and capabilities, and for letting us being part of your exciting projects in the past years. It is our desire to continue to keep you satisfied with our technology in the future. For this purpose, human antibody discovery and antibody engineering services using our technologies are now provided by our partner Yumab GmbH (www.yumab.com). Please contact Yumab for inquiries on future projects and orders.
12/2016 - Crystal structure of a human antibody from library HAL9
Erik Sundberg and Sandra Postel (University of Maryland) presented the X-ray crystal structure of a human immunglobulin Fab fragment binding to flagellar capping protein (FliD, UniProtKB: Q9K3C5) from Pseudomonas aeruginosa. The Fab fragment was derived by conversion
from the original scFv antibody fragment isolated by phage display from the HAL9 naive human monoclonal antibody library in the framework of an academic reserach collaboration. FliD is responsible for the adhesion of the bacterium to mucin, which is the initial event in colonization by this organism of the airways of cystic fibrosis patients.
11/2016 - Therapeutic human antibody pipeline news
CALYPSO Biotech SA, Switzerland (www.calypsobiotech.com) reports the successful generation of Anti-MMP-9 (Matrix metalloprotease 9) antibodies for their therapeutic pipeline by using our technology platform for the selection of human monoclonal antibodies. MMP-9 is a promising target for the treatment of Inflammatory Bowel Disease.
Reference: Goffin L, Fagagnini S, Vicari A,
Mamie C, Melhem H, Weder B, Lutz C, Lang S, Scharl M, Rogler G, Chvatchko Y,
Hausmann M. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment
of Inflammatory Bowel Disease Complications with Fibrosis. Inflamm Bowel Dis.
2016 Sep;22(9):2041-57. - Link to publication